CommercialAdministrativeLow impact
08.01.87a, Sutimlimab-jome (Enjaymo)
Independence Blue Cross·Hematology, Pharmacy·Pharmacy
We identified it
Jul 23, 2026
Summary
This is a reissue with no changes to the Independence Blue Cross policy for Sutimlimab-jome (Enjaymo). The policy was reviewed on 07/22/2026 and reissued to communicate the Company's continuing position on coverage for cold agglutinin disease (CAD). No billing codes, coverage criteria, or documentation requirements have been modified from the previous version.
Action Required
No immediate action required. This is a reissue with no substantive changes to the existing policy. Billing teams should verify that current systems reflect the HCPCS code J1302 (Injection, sutimlimab-jome, 10 mg) for claims submitted under this policy. Continue to apply the existing medical necessity criteria and documentation requirements when processing Enjaymo claims.